Skip to Content


In the US, Ilaris (canakinumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Familial Mediterranean Fever, Hyperimmunoglobulin D Syndrome, Juvenile Idiopathic Arthritis, Muckle Wells Syndrome and Tumor Necrosis Factor Receptor Associated Periodic Syndrome.

US matches:

UK matches:

Ingredient matches for Ilaris


Canakinumab is reported as an ingredient of Ilaris in the following countries:

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Canada
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Israel
  • Italy
  • Lithuania
  • Netherlands
  • Norway
  • Philippines
  • Poland
  • Portugal
  • Russian Federation
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.